Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM
NCT00597493
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
32
Enrollment
OTHER
Sponsor class
Conditions
Recurrent Glioblastoma Multiforme
Interventions
DRUG:
Sorafenib and Temozolomide
Sponsor
Duke University
Collaborators
[object Object]
[object Object]